ID
15349
Description
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany
Link
https://clinicaltrials.gov/ct2/show/NCT02419378
Keywords
Versions (3)
- 8/13/15 8/13/15 - Martin Dugas
- 5/24/16 5/24/16 -
- 5/28/16 5/28/16 -
Uploaded on
May 28, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Safety Assessment Multiple Sclerosis ALAIN01 NCT02419378
Safety Assessment Multiple Sclerosis ALAIN01 NCT02419378
- StudyEvent: SE
Description
Safety Lab. Assessments RQG
Description
Safety Lab. Assessments: Date
Data type
date
Alias
- UMLS CUI [1]
- C0011008
Description
Safety Lab. Assessments: Serum Creatinine
Data type
text
Alias
- UMLS CUI [1]
- C0201976
Description
Safety Lab. Assessments: Platelets
Data type
text
Alias
- UMLS CUI [1]
- C0005821
Description
Safety Lab. Assessments: TSH
Data type
text
Alias
- UMLS CUI [1]
- C0202230
Similar models
Safety Assessment Multiple Sclerosis ALAIN01 NCT02419378
- StudyEvent: SE
C0011008 (UMLS CUI [1,2])
C1705848 (UMLS CUI [1,2])
C0947611 (UMLS CUI [1,2])